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ABSTRACT
Genetic lesions affecting epigenetic regulators are frequent in myelodysplastic 
syndromes (MDS). Polycomb proteins are key epigenetic regulators of differentiation 
and stemness that act as two multimeric complexes termed polycomb repressive 
complexes 1 and 2, PRC1 and PRC2, respectively. While components and regulators 
of PRC2 such as ASXL1 and EZH2 are frequently mutated in MDS and AML, little is 
known about the role of PRC1.
To analyze the role of PRC1, we have taken a functional approach testing PRC1 
components in loss- and gain-of-function experiments that we found overexpressed 
in advanced MDS patients or dynamically expressed during normal hematopoiesis.
This approach allowed us to identify the enzymatically active component RING1A as 
the key PRC1 component in hematopoietic stem cells and MDS. Specifically, we found that 
RING1A is expressed in CD34+ bone marrow progenitor cells and further overexpressed 
in high-risk MDS patients. Knockdown of RING1A in an MDS-derived AML cell line 
facilitated spontaneous and retinoic acid-induced differentiation. Similarly, inactivation 
of RING1A in primary CD34+ cells augmented erythroid differentiation. Treatment with 
a small compound RING1 inhibitor reduced the colony forming capacity of CD34+ cells 
from MDS patients and healthy controls. In MDS patients higher RING1A expression 
associated with an increased number of dysplastic lineages and blasts. Our data suggests 
that RING1A is deregulated in MDS and plays a role in the erythroid development defect.
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INTRODUCTION
Myelodysplastic syndromes (MDS) are a 
heterogeneous group of clonal hematopoietic stem cell 
(HSC) disorders with a strong predisposition to acute 
myeloid leukemia (AML). MDS imply a defect of 
hematopoietic differentiation characterized by clinically 
apparent dysplasia in the bone marrow and cytopenias 
in the peripheral blood [1]. Based on the number and 
type of affected lineages, the number of dysplastic cells 
and undifferentiated blasts and the presence of frequent 
cytogenetic alterations, the world health organization 
(WHO) classifies MDS into several distinct subgroups [2]. 
The international prognostic scoring system (IPSS) and its 
revised version (IPSS-R) further incorporate cytogenetic 
information to stratify patients into risk groups with 
regard to prognosis (estimated overall survival and risk of 
progression to AML) [3, 4]. For the purpose of treatment 
strategy decisions, IPSS-R intermediate, high and very 
high are commonly summarized as higher-risk MDS. 
Once considered a rare disorder in the general population, 
MDS incidences are sharply rising with age making MDS 
the most frequent hematopoietic disorder in the elderly 
[5]. Secondary MDS can also arise in younger and older 
patients after aggressive cancer treatments with radiation 
or chemotherapy [6].
Current treatment options for MDS are limited. The 
only curative treatment for MDS patients is allogeneic 
HSC transplantation, which is not an option for many 
patients due to the high mortality associated with 
advanced age or the lack of suitable donors [6]. The 
immunomodulatory drug lenalidomide is effective in the 
low-risk subgroup of patients presenting an isolated loss 
of the long arm of chromosome 5, MDS del(5q) [7]. The 
DNA hypomethylating agent azacitidine is currently the 
standard of care for higher-risk MDS patients, but only 
50% of treated patients show hematological improvements 
and a complete response is limited to as few as 10% to 
15% (reviewed in [8]). Responses are transient with a 
median duration of 24 months and virtually all patients 
eventually relapse [9].
The heterogeneity of MDS, the frequent occurrence 
of age-related comorbidities and the limited treatment 
options make the management of MDS challenging. The 
development of novel targeted treatments based on a better 
understanding of the molecular pathogenesis of MDS is an 
unmet need.
Epigenetics is defined as the information that can 
be transmitted through the cell cycle independent of 
DNA sequence. Polycomb proteins are key epigenetic 
regulators of differentiation and stemness and frequently 
deregulated in cancer [10]. On the molecular level 
Polycomb proteins act as two multimeric complexes 
termed Polycomb repressive complexes 1 and 2, PRC1 
and PRC2, respectively. The general dogma posits that 
PRC2 and PRC1 act in a hierarchical and sequential 
manner. First, PRC2 trimethylates histone H3 on Lysine 
27 (H3K27me3) [11]. Second, this mark is recognized by 
PRC1 that catalyzes the monoubiquitination of histone 
H2A and mediates chromatin compaction and gene 
repression [12, 13].
The composition of PRC1 is much more variable 
than PRC2. Although PRC1 is composed of only four 
protein subunits, it is highly modular and 16 in part 
mutually exclusive components can hypothetically form 
180 different complexes [14]. The catalytically active 
RING1 subunit is either RING1A or RING1B, which 
forms the core complex by binding one of six Polycomb 
group of ring finger (PCGF) proteins. One of five possible 
CBX proteins provides the affinity for H3K27me3 and 
pairs with one of three PHC proteins. Non-canonical PRC1 
complexes contain RYBP or its homolog YAF2 instead of 
the CBX subunit and bind chromatin independently of 
H3K27me3 [15, 16].
MDS is caused by an age-dependent accumulation of 
genetic and epigenetic alterations in the HSC compartment 
[6, 17]. Gene lesions such as mutations, copy number 
changes or losses of heterozygosity have been detected in 
up to 95% of patients [5]. Genome-sequencing efforts of 
the last years have indicated that mutations affecting the 
epigenetic machinery are frequent in MDS [18, 19] with 
45% of all MDS patients harboring at least one mutation 
in an epigenetic regulator [5]. In particular, inactivating 
mutations in genes encoding components and regulators of 
PRC2 such as EZH2 and ASXL1 are particularly frequent 
[17, 20, 21]. In contrast, no mutations have been found in 
PRC1 components.
Here, we have systematically analyzed the 
expression of all genes encoding components of PRC1 
complexes and functionally studied a panel of PRC1 
components that were overexpressed in MDS or 
dynamically expressed during normal hematopoiesis. This 
approach allowed us to identify RING1A as key PRC1 
component in hematopoietic stem/progenitor cells (HSPC) 
and motivated us to evaluate the potential of RING1A as 
drug target for the treatment of MDS.
RESULTS
PRC1 components are differentially expressed in 
higher-risk MDS and during differentiation
In order to characterize the function of PRC1 
components in the pathogenesis of MDS, we analyzed 
the expression of genes encoding its components (for 
simplicity referred to as canonical PRC1 genes) in 
the hematopoietic stem/progenitor cell compartment 
of MDS patients and healthy controls and during 
normal hematopoiesis. In our analysis we have further 
included genes encoding components of PRC2 and 
proteins that were identified in non-canonical PRC1 
complexes [16].
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Long-term HSC (LT-HSC) are the most primitive 
HSC in a hierarchy of differentiation, with each 
subsequent cell type becoming more specialized [22]. LT-
HSC as well as hematopoietic progenitors are enriched in 
the population of bone marrow cells expressing the CD34 
surface marker [22]. In order to identify deregulations 
of individual genes, we used two datasets to compare 
the expression in CD34+ cells between healthy controls 
and high-risk MDS [23, 24]. These studies included 
MDS cases classified as refractory anemia with excess 
blasts 2 (RAEB-2) that correspond to MDS with excess 
blasts 2 (MDS-EB2) according to the revised 2017 WHO 
classification [2]. The genes most overexpressed in RAEB-
2 included the canonical PRC1 components RING1A and 
CBX6 (Figure 1A). RING1A was also overexpressed in 
refractory anemia (RA) with ringed sideroblasts (RARS) 
but not in RA or RAEB-1 (Supplementary Figure 1A). 
Direct comparison of the probe intensities further 
suggested that RING1A is the predominantly expressed 
catalytic subunit of PRC1 (Supplementary Figure 1B). 
EZH2 was the top downregulated gene in RAEB-2 
(Figure 1A) and also scored significantly downregulated 
in the other MDS subtypes (Supplementary Figure 1A). 
Next, we were interested to understand to which extent 
the expression of PRC1 component encoding genes is 
dynamic during hematopoietic differentiation. For this 
we made use of an expression dataset of isolated bone 
marrow cell populations that represent eight sequential 
stages in the differentiation from HSC to fully mature 
polymorphonuclear granulocytes [25]. When focusing 
on canonical PRC1 genes, unsupervised hierarchical 
clustering divided the genes in four clusters (Figure 
1B). The cluster of the most downregulated genes 
contained RING1A, RING1B, BMI1 and PHC1, while 
PCGF3, PHC2 and CBX7 were grouped together 
as those genes that were most upregulated during 
granulocytic differentiation (Figure 1B). In addition to 
these canonical PRC1 genes also many genes encoding 
components of the non-canonical PRC1 complexes were 
dynamically expressed during granulocytic differentiation 
(Supplementary Figure 2).
Taken together we have identified a subset of PRC1 
genes that are highly expressed in the hematopoietic stem/
progenitor compartment, overexpressed in MDS and 
dynamically regulated during granulocytic differentiation. 
Based on these results we have selected RING1A, BMI1, 
CBX6 and CBX7 for further analysis.
Genetic perturbation studies in AML/MDS cells 
identify RING1A as key PRC1 component
MDS is characterized by defective hematopoietic 
differentiation. In order to test an influence of selected 
PRC1 components we decided to take a functional 
approach and studied the influence of genetic perturbations 
on the differentiation status and capacity of a model 
cell line. In a previous study we have characterized the 
immunophenotypes, cytogenetic and mutational profiles 
of a panel of MDS/AML cell lines that were derived from 
MDS patients after progression to AML [26]. For several 
reasons, we have selected the SKK-1 cell line as a suitable 
cell line to study the function of PRC1: First, SKK-1 cells 
express the pluripotency marker CD117 but are negative 
for most differentiation markers of the monocytic, 
granulocytic, megakaryocytic and erythroid lineages 
indicating their non-differentiated state. Second, SKK-1 
cells have no mutations in the PRC2 components EZH2, 
EED, SUZ12 or its regulator ASXL1 [26]. Although SKK-
1 cells have lost one copy of EZH2 [26], the remaining 
copy of EZH2 is wild-type and cells are positive for 
H3K27me3 [20], suggesting that the PRC2 complex 
is intact and functional. Third, we found that SKK-1 
showed a partial response to the differentiation cue all-
trans retinoic acid (ATRA) reflected in a reduction of the 
proportion of CD117+ cells as assessed by flow cytometry 
(Figure 2A). In terms of cytology, we observed a reduction 
in basophilia after May-Grünwald-Giemsa staining 
(Supplementary Figure 3A), a further characteristic of 
differentiation [27].
To evaluate the function of PRC1 genes, we used 
RNA interference to reduce the levels of RING1A, 
CBX6 and BMI1, which were highly expressed in CD34+ 
cells (Supplementary Figure 1B) and in the case of 
RING1A and CBX6 also overexpressed in MDS RAEB-
2 (Figure 1A). As controls, we have included the PRC2 
component EZH2 and the PRC2 regulator ASXL1. Using 
a lentiviral system and small hairpin RNAs (shRNAs) 
embedded in an optimized miRNA backbone [28], we 
achieved a significant reduction of the levels of the 
targeted mRNAs (Figure 2B). Furthermore, we decided 
to increase the expression of CBX7 that we found to be 
less expressed in CD34+ cells and further upregulated 
during differentiation (Supplementary Figure 1B and 
1B). For this, we employed a modified CRISPR-Cas9 
complex that allows the activation of the endogenous 
gene by RNA guided recruitment of transcriptional 
activators [29]. This technique allowed us to induce the 
expression of CBX7 approximately 8-fold (Figure 2C). 
Next we analyzed the influence of these manipulations 
on the differentiation state by reading out the number 
of cells displaying CD117 in steady-state growth 
conditions and after treatment with ATRA. Of all these 
genetic perturbations the knockdown of RING1A had 
the strongest influence and reduced the proportion of 
CD117+ cells and the overall expression of the CD117 
before and after treatment with ATRA (Figure 2D and 
Supplementary Figure 3B). Knockdown of CBX6 had 
less effect in reducing the proportion of CD117+ cells 
only detectable by flow cytometry and after ATRA 
treatment (Figure 2D). Taken together, these results 
prompted us to focus our study on RING1A as a key 
candidate component of canonical PRC1 in MDS.
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The influence of RING1A on differentiation is 
isoform-specific
In order to further validate our findings, we repeated 
the suppression of RING1A in SKK-1 cells with a different 
shRNA and further also included one shRNA against the 
closely related isoform RING1B. As shown in Figure 3A, 
both RING1A and RING1B proteins are easily detected in 
SKK-1 cells and their expression was efficiently suppressed 
in cells transduced with the targeting shRNA vectors (Figure 
Figure 1: Expression analysis of PRC1 genes in MDS and differentiation. (A) Logarithmic fold change in expression 
of probes for canonical PRC genes and components of non-canonical complexes in MDS classified as refractory anemia with 
excess blasts 2 (RAEB-2) compared to healthy controls. Two datasets [23, 24] were analyzed and only significant fold-changes 
(FC, p-value < 0.05) are shown. When significant in both datasets, the mean is plotted and the variation indicated by error bars. 
(B) Heatmap representing RNA expression of canonical PRC1 components during normal granulocytic differentiation [25]. Cell 
populations isolated from healthy bone marrow correspond to sequential steps in granulocytic differentiation that are hematopoietic 
stem cell (HSC), common myeloid progenitor (CMP), granulocyte-macrophage progenitor (GMP), early promyelocyte (early PM), 
late promyelocyte (late PM), metamyelocyte (MM), band cell (BC) and polymorphonuclear (PMN) mature granulocyte (n = 3-5). For 
all PRC1 genes see Supplementary Figure 2.
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3A). Interestingly, the knockdown of either RING1A or 
RING1B led to an increase in the other protein. A possible 
explanation for this observation might be provided by 
reported negative feedback loops in which Polycomb 
complexes repress the expression of genes encoding other 
Polycomb proteins [30]. Importantly, when treating SKK-
1 cells with ATRA both shRNAs directed against RING1A 
reduced the number of CD117+ cells, while the similarly 
efficient shRNA against RING1B had no effect (Figure 
3B). Conversely, the mRNA level of the myelomonocytic 
differentiation marker CD11b was elevated in ATRA-treated 
SKK-1 cells and further increased in RING1A knockdown 
cells (Figure 3C). Similarly, CD11b mRNA was also 
increased in phorbolester-induced Kasumi-1 acute myeloid 
leukemia cells and this increase was higher when cells were 
transfected with a pool of specific siRNAs for RING1A but 
not RING1B (Figure 3D). Together these results further 
support a role for RING1A in limiting cellular differentiation.
Figure 2: Genetic perturbation of PRC components in an MDS/AML cell line. (A) SKK-1 cells respond to the treatment 
with 1μM ATRA by diminishing the levels of the pluripotency marker CD117, which was assessed by flow cytometry. (B) Knockdown 
efficiency of different shRNAs against PRC1 (RING1A, CBX6 and BMI1) and PRC2 (EZH2 and ASXL1) components. Data for CBX6, 
BMI1, EZH2 and ASXL1 shRNAs represents an average from two different shRNA sequences for each gene. The relative expression of the 
corresponding mRNA assessed by qRT-PCR compared to control cells (ctrl) was set to 1. Data is represented as mean + SD (n ≥ 4; *, p<0.05 
compared to control). (C) Overexpression of endogenous CBX7 using engineered CRISPR-Cas9 synergistic activation mediator (SAM). 
Data is plotted as in B. Data is represented as mean of three biological replicates + SD (*, p<0.05 compared to control). (D) Genetically 
perturbed SKK-1 cells shown in B and C were treated with ATRA as in A or left untreated. The percentage of CD117+ cells was assessed 
by flow cytometry. Data is represented as mean + SD (n ≥ 3; *, p<0.05 compared to control).
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RING1A limits differentiation in the 
hematopoietic stem cell compartment
To further analyze the function of RING1A in 
hematopoiesis, we decided to analyze its role in primary 
HSPC. For this we enriched hematopoietic stem and 
progenitor cells by isolating CD34+ cells from the bone 
marrow from healthy donors. Using the same lentiviral 
knockdown strategy to suppress the expression of 
RING1A, we isolated transduced cells by sorting for the 
fluorescent marker GFP present on the vector. Analyzing 
these cells by flow cytometry after six days in culture, 
we observed an enrichment of cells positive for a mix 
of lineage markers compared to empty vector control 
cells suggesting spontaneous differentiation (Figure 
4A). Cytologic analysis of these cells indicated that this 
included both granulocytic and erythroid differentiation 
(Figure 4B). To test whether the knockdown of RING1A 
would preferentially affect one of these lineages, we 
seeded the manipulated cells into methylcellulose and 
assessed the number and type of colonies. Specifically, we 
found that knockdown of RING1A significantly increased 
the number of erythroid colonies (BFU-E, units formed 
by erythroid progenitors), while leaving the number of 
granulocyte-macrophage colonies (CFU-GM) unaffected 
(Figure 4C). To test whether suppression of RING1A 
also affects LT-HSC, we assessed the colony forming 
capacity of manipulated CD34+ cells after 6 weeks in 
long-term culture on supportive stroma cells (Figure 
4D). This assay provides a suitable approximation of the 
number of primitive LT-HSC. We observed that under 
these experimental conditions the number of colonies was 
markedly reduced in RING1A-depleted cell populations. 
Taken together, these results suggest that genetic RING1A 
inhibition in CD34+ cells leads to the depletion of the 
LT-HSC pool by increasing cellular differentiation, in 
particular towards the erythroid lineage.
Pharmacological inhibition of RING1A 
depletes progenitors during induced erythroid 
differentiation
The identification of novel therapeutic targets 
and the development of targeted strategies are urgently 
required to improve the management of MDS. Thus, 
we wondered whether pharmacological inhibition of 
RING1A has a therapeutic window for the treatment of 
MDS. Since RING1A is the enzymatically active subunit 
of PRC1 it is well suited for the inhibition with synthetic 
small compound inhibitors. Until now PRT4165 is the 
only reported small compound inhibitor of PRC1 and was 
shown to inhibit the H2A ubiquitin ligase activity of both 
RING1A and RING1B [31]. We first confirmed that the 
reported dose of PRT4165 was effective in SKK-1 cells 
and able to reduce the levels of ubiquitinated H2A and 
– possibly by inducing degradation – of PRC1 complex 
components (Figure 5A). In order to assess the potential 
of RING1A as drug target we compared the influence 
of PRT4165 treatment on MDS patient-derived CD34+ 
bone marrow cells with control HSPC from healthy 
donors. Specifically, we assessed differentiation capacity 
focusing on the erythroid lineage and the total number 
of colony-forming cells. For the differentiation analysis 
we analyzed the number of cells expressing the erythroid 
differentiation marker CD36+ after 14 days of culture with 
early-acting growth factors followed by induction with 
erythropoietin for 7 days. In healthy samples, on average, 
60% of the cells were positive for CD36 and this number 
was significantly increased after co-administration of 
PRT4165 (Figure 5B). In contrast, in MDS patient samples 
the induction of CD36+ cells was severely impaired and 
not affected by PRT4165 treatment (Figure 5B). When 
plating erythropoietin-induced cells in methylcellulose 
the co-treatment with PRT4165 resulted in a depletion of 
colony-forming progenitor cells, which was comparable in 
MDS and healthy controls (Figure 5C). While these results 
further support a role of RING1A-containing PRC1 in the 
maintenance of stem and progenitor cells by limiting their 
differentiation, they also indicate that the only currently 
available inhibitor does not favorably discriminate 
healthy from diseased cells and cannot overcome the 
differentiation defect in MDS.
RING1A expression is associated with number of 
cytopenias in MDS patients
MDS is characterized by dysplasia in the bone marrow 
and cytopenia in the peripheral blood, affecting one or more 
lineages. Since RING1A limited differentiation of in vitro 
culture of both primary CD34+ cells and an established MDS/
AML cell line, we wondered whether in MDS patients the 
levels of RING1A would correlate with the severity of the 
disease. We took advantage of previously generated expression 
data from mononuclear bone marrow cells from 139 MDS 
patients for which clinical data was well documented as 
part of the MILE study [32]. As shown in Figure 6A, the 
expression of RING1A was significantly increased in MDS 
patients displaying dysplasia in more than one lineage. In 
agreement with an earlier study [33], we found RING1A levels 
correlating with blast counts when comparing cases with 
low and intermediate counts (Figure 6B). In contrast to the 
same report, the differences in RING1A expression between 
different IPSS risk groups did not reach significance (Figure 
6C). The expression level of RING1A was not associated with 
the type of chromosomal abnormalities (Figure 6D).
Our results indicate that the capacity of RING1A 
to inhibit differentiation in vitro is also reflected in MDS 
patients where higher RING1A levels correlated with a 
higher number of dysplastic lineages, and thus likely a 
higher number of cytopenias and greater severity of the 
disease. This suggests that the overexpression of RING1A 
in MDS may indeed be clinically relevant.
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DISCUSSION
RING1A is a key PRC component in the 
hematopoietic stem cell compartment and MDS
In our study we have combined data mining of MDS 
patient cohorts and functional studies in primary cells and 
in an established MDS/AML cell line to investigate the 
genes encoding the components of PRC1. Taken together, 
our results suggest that RING1A is a key component of 
the PRC1 complex during normal hematopoiesis and 
in MDS. First, of the two enzymatic subunits of PRC1, 
RING1A is highest expressed in CD34+ HSC and further 
overexpressed in cells from MDS patients with RAEB-
2. Second, during normal granulocytic differentiation 
Figure 3: The influence of RING1A on differentiation is isoform-specific. (A) Immunoblot analyses of RING1A and RING1B 
in total lysates of SKK-1 cells transduced with shRNA cassettes for RING1A, RING1B and a control hairpin (sh ctrl). An anti-Histone H3 
immunoblot has been included to control for the protein content of samples. The shRNA against RING1A previously used (Figures 2 and 
Supplementary Figure 3) is here referred to as #1. (B) SKK-1 sh control (ctrl), shRING1A#1, shRING1A#2 and shRING1B#1 cells were 
treated or not with 1 μM ATRA for two days and the percentage of CD117+ cells was assessed by flow cytometry. Data is represented as mean + 
SD (n ≥ 4; *, p < 0.05). (C) The mRNA level of CD11B was analyzed in infected SKK-1 cells after 4 days of ATRA treatment. qRT-PCR data is 
presented as mean + SD (n = 4; *, p < 0.05). (D) The mRNA level of CD11B was analyzed in siRNA transfected Kasumi-1 cells treated with 200 
nM phorbolmyristateacetate (PMA) for 24 hours or DMSO vehicle (untreated). qRT-PCR data is presented as mean + SD (n = 3; *, p < 0.05).
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RING1A is progressively downregulated. Third, inhibition 
of RING1A by RNA interference – but not inhibition of 
RING1B or other tested PRC1 genes – increased the 
differentiation of SKK-1 cells, an established MDS/AML 
cell line. Fourth, both genetic and chemical inhibition 
of RING1A increased the differentiation of healthy 
CD34+ bone marrow cells towards the erythroid lineage. 
Finally, in MDS patients higher RING1A expression was 
associated with a higher number of dysplastic lineages and 
blast counts > 5%.
Of note, van den Boom and colleagues previously 
assessed the function of various PRC1 subunits in 
human CD34+ cells isolated from cord blood [34]. They 
reported that when performing colony-forming assays, 
knockdown of several PRC1 components including the 
alternate catalytic subunit RING1B caused a shift towards 
the granulocytic-macrophage lineage in colony forming 
assays. Here, we have observed the opposite phenotype 
– a shift towards erythroid colonies - when knocking 
down RING1A. This suggests that differently composed 
PRC1 complexes might limit the commitment to specific 
blood lineages and conversely favor others. RING1A-
containing PRC1 complexes seem to preferentially inhibit 
differentiation towards the erythroid lineage.
In our study, we have included CBX6 which we 
found upregulated in RAEB-2 patients. Knockdown of 
Figure 4: RING1A knockdown in primary healthy bone marrow CD34+ HSC. (A) Percentage of lineage positive cells was 
measured by flow cytometry using of Lineage mix antibodies (CD4, CD8, CD15, CD19, CD41 and CD235alpha), comparing CD34+ cells 
transduced with control and shRING1A #1. (B) May-Grünwald-Giemsa staining of the same cells as A indicates both granulocytic (G) and 
erythroid (E) differentiation. A few examples are indicated. Erythroid cells show darker cytoplasm as a hallmark of hemoglobin synthesis. 
In particular during granulocytic differentiation, the ratio of cytosol to nucleus increases. (C) Colony forming assay in methylcellulose 
comparing control and shRING1A#1 transduced CD34+ cells. Data is represented as mean + SD (n = 3; *, p < 0.05). CFU-GM, colony-
forming-unit-granulocyte, macrophage; BFU-E, burst-forming-unit-erythroid. (D) Long-term culture colony-forming cells (LTC-CFC) of 
control and shRING1A#1 CD34+ cells after 6 weeks on stroma cell-supported culture. Data is represented as mean + SD (n = 4; *, p < 0.05 
paired, one-tailed T-test).
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CBX6 promoted differentiation in SKK-1 cells albeit 
to a lesser extent than RING1A and only when treated 
with ATRA. However, several studies have shown that 
CBX6 preferentially associates with non-PRC proteins 
and thus questioned the role of CBX6 as canonical 
PRC1 component [35, 36]. In hepatocellular carcinoma 
CBX6 overexpression contributes to tumor progression 
and is predictive of a poor prognosis [37]. Thus, it will 
be interesting to continue the analysis of CBX6 in MDS 
although its role might not be related to PRC1 function.
Taken together, our results suggest that in normal 
hematopoiesis and MDS RING1A is a key component of 
PRC1 whose function is likely further modulated by its 
other components.
Can PRC genes serve as prognostic markers?
Revised International Prognostic Scoring System 
(IPSS-R) has achieved international acceptance to estimate 
prognosis in MDS patients [4]. In addition to bone marrow 
blast percentage and the number of peripheral cytopenias, 
the IPSS-R is strongly based on cytogenetic information. 
A major challenge for the field is to further improve 
this prognostic scoring system by the incorporation 
Figure 5: Differential influence of RING1 inhibitor PRT4165 in healthy and MDS cells. (A) Western blot. To test the 
functionality of the RING1 inhibitor PRT4165, SKK-1 cells were treated with different concentrations or DMSO (ctrl) for six hours. Levels 
of PRC1 proteins and ubiquitinated H2A, the histone modification catalyzed by RING1 proteins, were analyzed by immunoblotting. 
Histone H3 served as loading control. (B) CD34+ HSPC from bone marrow of MDS patients (n=9) and healthy donors (n=4) were treated 
with 12.5μM PRT4165 or DMSO (control) for two weeks and with 2U/ml erythropoietin during the second week. The percentage of cells 
expressing the erythroid differentiation marker CD36 was assessed by flow cytometry. *, p<0.05. (C) Same cells as in B were plated after 
treatment into methylcellulose and colonies were counted after 14 days of seeding. *, p<0.05. CFU, colony-forming-unit.
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of molecular information. The mutation status and 
the expression level of several PRC components and 
regulators have been found associated with disease stage, 
progression or response to treatment (recently reviewed 
in [38]). For instance, mutations in the PRC2 genes EZH2 
and ASXL1 correlate with poor overall survival in MDS 
patients, independently of established risk factors, such 
as age, WHO classification or IPSS [18]. The levels of 
the PRC1 component BMI1 are associated with high-
risk MDS with excess blasts and patients with lower risk 
MDS subtypes were more likely to progress when BMI1 
levels were high [39]. Analyzing a cohort of 54 MDS 
patients Xu and colleagues reported that the expression of 
BMI1, EZH2 and RING1A was higher in high-risk MDS 
compared to low-risk MDS and associated with increased 
IPSS score [33]. Analyzing larger cohorts we were able 
to confirm the overexpression of RING1A in MDS 
with excess blasts (Figure 1A) but found no significant 
association with IPSS scoring (Figure 6C). Specifically, 
both Xu et al and we observed higher RING1A expression 
in patients with 5-10% of blasts compared to those with 
less than 5% but could not observe any further increase 
when analyzing pre-leukemic patients with 11-20% blasts. 
In contrast to the same study but in accordance with 
another [40], we found EZH2 significantly downregulated 
in MDS RAEB-2 (Figure 1A) but also in subtypes 
associated with lower risk (Supplementary Figure 1A). 
The downregulation of EZH2 parallels the frequent 
Figure 6: RING1A expression is associated with the number of dysplastic lineages. (A-D) Boxplots showing the expression 
of RING1A in patients grouped according to clinical characteristics [32]. For the number of patients that were considered in each category 
please see Supplementary Table 1. The same probe that scored different in Figure 1A was analyzed and the binary logarithm of its intensity 
is plotted as an indirect measure of gene expression. *, p < 0.05 using parametric unpaired T-test. A. RING1A expression according to 
number of lineages affected by dysplasia at diagnosis. B. RING1A expression according to percentage of blasts in bone marrow. C. 
RING1A expression according to IPSS scoring system [3]: 0.5 to 1.0, intermediate-1; 1.5 to 2.0, intermediate-2; and ≥2.5, high. D. RING1A 
expression according to karyotype with more than 3 alterations being considered as complex.
Oncotarget115012www.impactjournals.com/oncotarget
inactivation of the gene by mutations [20, 21] and suggests 
that reduced PRC2 function is a more general hallmark of 
MDS than previously appreciated.
The expression of PRC genes is intimately linked to 
cell proliferation (discussed in [41]). First, proliferation-
promoting signaling pathways upregulate the expression 
of some PRC genes. Second, PRCs promote proliferation 
through repressing the INK4-ARF locus, which encodes 
key cell cycle inhibitors. Thus, overexpression of 
PRC genes might be a consequence of an increased 
proliferation rate and less informative than direct markers 
of cell proliferation. Proliferation rates tend to decline 
with an advance in differentiation [22]. The finding 
that in particular PRC1 genes are upregulated during 
differentiation argues against an over-simplification of the 
relation between PRC gene expression and proliferation. 
More complex scenarios need to be considered in which 
changes in PRC1 composition allow them to perform cell-
type and gene-specific functions.
In conclusion, the relation of PRC gene expression 
and MDS progression is complex as some PRC genes 
are upregulated in MDS while others are disrupted or 
downregulated. Future studies will need to carefully assess 
whether measuring mRNA levels and mutations status of 
PRC genes can add value to the current prognostic scoring.
Is RING1A a drug target for MDS therapy?
Most chemotherapeutic agents target actively 
dividing cells. Thus, leukemic stem cells are relatively 
resistant to these kinds of drugs, contributing to treatment 
failure and ultimately patient death. Targeting pathways 
that are especially important for leukemic stem cells 
may offer a better therapeutic option for the patient [42]. 
Epigenetic therapy, that means strategies interfering with 
the chromatin regulation, has started to receive increasing 
interest [43]. DNA demethylating agents azacitidine and 
decitabine have been approved for the treatment of MDS 
[8] and the histone deacetylase inhibitor vorinostat is used 
for cutaneous T-cell lymphoma therapy [44]. Inhibitory 
compounds targeting components of PRCs are under 
development. In particular for PRC2’s enzymatically 
subunit EZH2, several inhibitors have shown promising 
pre-clinical results and now entered into clinical 
trials for solid cancers in which EZH2 is frequently 
overexpressed [45]. RING1A and RING1B provide the 
catalytic activity to PRC1 and are thus amenable for 
pharmacologic inhibition. Based on two observations 
we decided to evaluate the potential of RING1A as drug 
target for MDS. First, RING1A is overexpressed in MDS 
with excess blasts. Second, RNA interference mediated 
suppression of RING1A facilitated the differentiation 
of an MDS/AML cell line and of primary bone marrow 
HSPC (Figure 2 and 3). For this we used the only 
current available inhibitor PRT4165 [31]. Although the 
inhibitor is effective as shown by a pronounced reduction 
in RING1A-mediated ubiquitination of histone H2A, 
rather high and micromolar concentrations are required. 
Although PRT4165 is far from being a usable drug in the 
clinic, it serves as a tool compound and a lead structure 
for further synthetic improvement. When comparing the 
influence of PRT4165 on HSPC from MDS patients to 
healthy donors, we observed that it depleted the stem 
cell compartment in both MDS and healthy donor cells. 
While PRT4165 further increased erythropoietin-induced 
erythroid differentiation in healthy bone marrow cells, the 
influence of erythropoietin was severely impaired in MDS 
cells and not further affected by PRT4165 (Figure 5B and 
5C) likely reflecting the complex differentiation defect, 
which is a hallmark of MDS. These results support a key 
role for RING1A in early hematopoiesis but also indicate 
that its pharmacologic inhibition has a limited therapeutic 
window as a single agent. When given in combination 
with a drug that discriminates between healthy and 
diseased stem cells, RING1A inhibition might have a 
more favorable enhancing effect. Others have obtained 
similar results testing the inhibition of BMI1, the PCGF 
component of PRC1 predominantly expressed in CD34+ 
bone marrow cells (Supplementary Figure 1B). Kreso and 
colleagues have used a compound that inhibits the BMI1 
mRNA transcript by a yet unknown mechanism [46] 
which reduces the viability of both healthy and diseased 
bone marrow cells [47].
Chromosomal abnormalities involving gains and 
losses of gene copies are frequent in MDS [5]. Given the 
large number of PRC genes, these alterations frequently 
affect PRC genes. SKK-1 cells for instance have three 
copies of PHC1 but only one copy of EZH2 and PCGF3 
[26]. It will be interesting to test whether reduced dosages 
of key PRC components can be exploited for synthetic 
lethality approaches. It remains to be seen whether 
haploinsufficiency of SKK-1 cells for the catalytic PRC2 
component EZH2 contributed to the sensitivity to PRC1 
inhibition that we observed here.
Our and previous work show that PRC1 complexes 
containing RING1A, most likely together with BMI1, are 
emerging as key epigenetic regulators of differentiation 
in HSPC. The enzyme RING1A is amenable for 
pharmacologic inhibition but the therapeutic potential of 
inhibiting PRC1 will likely be limited to combinations 
with other disease-specific drugs.
MATERIALS AND METHODS
Antibodies and plasmids
The following antibodies were used for 
immunoblotting in a dilution of 1:500 (if not indicated 
otherwise): anti-RING1A (Abcam, ab32644), anti-
RING1B (kindly provided by Luciano di Croce and 
described in [48]), anti-ubiquitinated H2A (Cell signaling, 
#8240), and anti-histone H3 (Abcam, ab1791, dilution 
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1:10.000). Conjugated antibodies used for flow cytometry 
are listed in Supplementary Information Supplementary 
Table 2.
ShRNAs have been inserted into the lentiviral 
SGEP vector following the described cloning 
protocol [28]. For a list of all used shRNAs please see 
Supplementary information Supplementary Table 3. 
Vectors encoding the modified CRISPR/SAM (Addgene) 
and the cloning protocol for the design and insertion 
of the guide strand have been described [29]. For the 
production of lentiviral particles we used packaging 
plasmids psPax2 (Addgene #12260) and pCMV-VSV-G 
(Addgene #8454).
Cell culture
The MDS/AML SKK-1 cell line was obtained 
from the Leibniz-Institute DSMZ-German Collection 
of Microorganisms and Cell Cultures (Braunschweig, 
Germany) and cultured at 37ºC in 5% CO2 in non-treated 
flasks for suspension cells using RPMI 1640 medium 
(Gibco). HEK293T cells were obtained from ATCC 
and cultured in DMEM. Media were supplemented 
with 10% fetal bovine serum (Gibco), 1% penicillin-
streptomycin (Gibco) and 1% L-Glutamine (Gibco). 
Cells were authenticated and passaged for less than 6 
months. To induce differentiation SKK-1 cells at an initial 
concentration of 0.5x106 cells/mL were treated with 1μM 
ATRA (Sigma-Aldrich) for 2-4 days.
The AML Kasumi-1 cell line was obtained from 
ATCC and cultured at 37ºC in 5% CO2 in non-treated 
flasks for suspension cells using RPMI 1640 medium 
(Gibco). Media was supplemented with 20% fetal bovine 
serum (Gibco), 1% penicillin-streptomycin (Gibco) 
and 1% GlutaMAX (Gibco). To induce differentiation, 
Kasumi-1 cells were treated with 200 nM PMA (Sigma-
Aldrich) for 24 hours.
Isolation and culture of CD34+ primary bone 
marrow cells
Ficoll separation was performed to isolate 
mononuclear cells from bone marrow samples obtained 
from MDS patients or healthy donors following informed 
consent and under institutional review board guidelines. 
CD34+ cells were isolated from mononuclear cells 
using magnetic beads CD34+ separation protocol (CD34 
MicroBead Kit human, MACS Miltenyi Biotec). Isolated 
CD34+ bone marrow cells were kept in cell culture at 37ºC 
in serum-free medium containing 20% BIT9500 (Stemcell 
Technologies), 80% IMDM medium with Glutamax 
(Gibco), 10μM ß-Mercaptoethanol (Gibco), 8μg/mL 
ciprofloxacin (Fresenius Kabi) and 5 growth factors: 
100ng/mL stem cell factor, 100ng/mL FLT3-Ligand, 25ng/
mL thrombopoietin (TPO), 10ng/mL interleukin 3 and 
10ng/mL interleukin 6 (R&D systems).
Gene transduction
Infections were essentially carried out as described 
[49]. In brief, viral supernatants were harvested from 
transfected HEK293T cells. Filtered lentiviral supernatants 
were mixed with cells at a final concentration of 0.5 x 
106 cells/mL in 6-well plates while centrifuging at 1200 
rpm for 45 minutes at 37ºC in the presence of 8μg/mL 
polybrene (Sigma-Aldrich). The infection process was 
repeated after 24 hours. For the infection of CD34+ 
primary cells we used retronectin-bound virus method 
(TaKaRa clontech), in which lentiviral particles are first 
bound to the plate coated with RetroNectin reagent, 
and the target cells are added after removing the virus 
supernatant. In this way, the viral supernatant was added 
to the Retronectin coated and blocked plates. The plate 
was centrifuged during 2 hours at 32ºC 1000-2000g. The 
viral supernatant was removed and CD34+ primary cells 
were added to each well and centrifuged for 5 minutes to 
spin them down. Second infection hit was repeated after 
24 hours. Infected CD34+ cells were cultured in serum-
free medium as described above, 6 days after the first 
infection, GFP+ cells were sorted using FACSAria III cell 
sorter (Becton Dickinson). Infected SKK-1 were selected 
with 1 μg/mL puromycin (Sigma-Aldrich) 24 hours after 
the first infection.
Transient transfection of Kasumi-1 cells with a 
pool of 4 siRNAs against RING1A, RING1B or non-
targeting control (GE Dharmacon) was performed with 
the electroporation-based Neon transfection system 
(ThermoFisher Scientific), following the suppliers’ 
instructions. For a list of siRNAs used please see 
Supplementary information Supplementary Table 3.
Endogenous gene activation using CRISPR/SAM
For the activation of an endogenous gene locus, 
we have used CRISPR/Cas9 Synergistic Activation 
Mediator (CRISPR/SAM), an engineered protein 
complex described elsewhere [29]. Following authors’ 
protocol, cells were transduced with two lentiviral vectors 
(dCas9-VP64-blasticidin, Addgene #61425; and MS2-
p65-HSF1-hygromycin, Addgene #61426) and selected 
with 2μg/mL blasticidin (Sigma-Aldrich) and 100μg/mL 
hygromycin B (Invitrogen) during 7 days. Once selected, 
a second lentiviral transduction was performed with a 
plasmid encoding a small guide RNA (sgRNA) of interest 
(Addgene #61427) into the cells stably expressing dCas9 
and MS2. Finally, cells were selected with 25μg/mL 
zeocin (EMD Millipore) for 7 days and endogenous gene 
activation was analyzed by qRT-PCR or immunoblotting.
RNA and protein analysis
The analysis of RNA and proteins was performed 
essentially as previously described [50].
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Flow cytometric analysis of differentiation
We assessed CD117 expression of infected SKK-
1 cells by using PE Mouse anti-human CD117 antibody 
(BD Pharmingen) and we analyzed the CD117+ cells in 
the GFP+ population, in LSR Fortessa (Becton Dickinson) 
flow cytometer. A minimum of 10000 events of every 
sample were analyzed.
To assess the lineage commitment of primary 
CD34+ cells, we incubated them first with a mix of biotin-
labeled antibodies of lineage markers that included CD4, 
CD8, CD15, CD19, CD235alpha and CD56 antibodies. 
Fluorophor-couped streptavidin was added. After washing, 
cells were analyzed in HF2 buffer (HBSS 1x, 2% FCS 
(Biochrom), 10mM Hepes, 1% penicillin-streptomycin) 
containing 1μg/mL propidium iodide (PI) (Sigma-Aldrich) 
to exclude PI+ dead cells, were analyzed by flow cytometry 
(CyAn Beckman coulter cytometer). For analysis of 
erythroid differentiation, cells were labeled with anti-
CD36. For a detailed list of all antibodies, sources and 
dilutions please see Supplementary Info Supplementary 
Table 2. Analysis was performed using FlowJoTM software.
Colony formation
1500 primary CD34+ cells were plated into 
methylcellulose. For this, cells were first diluted in 
300μL serum-free medium (adding inhibitor or vehicle if 
indicated) and then added to 3000μL of methylcellulose 
(StemMACS HSC-CFU complete with Epo, 130-091-
280, Miltenyi Biotech) and divided into 2 plates. Dishes 
were incubated at 37°C and colonies were counted and 
classified after 14 days using standard criteria.
Long-term culture assay
At day 0, EL08-1D2 murine stroma cells were 
plated in 6-well plates (0.4x106 cells/well) in stroma 
medium (80% Alpha MEM medium (Gibco), 15% FCS 
(Biochrom), 5% horse serum (Stemcell technologies), 1% 
penicillin-streptomycin and 10μM β-mercaptoethanol). At 
day 2, when cells were confluent, they were irradiated (30 
Gy) and media was changed for fresh medium. At day 9, 
medium was removed and 10000 to 20000 GFP+ CD34+ 
cells (control or shRING1A) were added in LTC-medium 
(2mL/well), containing 50mL Myelocult medium (H5100 
#05100, Stemcell technologies), 10ng/mL FLT3-ligand 
(R&D systems), 20ng/mL TPO (R&D systems), 1μM 
hydrocortisone (Pfizer), 8μg/mL ciprofloxacin (Fresenius 
Kabi) and 1% L-glutamine (Gibco).
Half of the media was replaced every week (once a 
week) with fresh media for 6 weeks, carefully removing 
800μL supernatant and adding 1mL of fresh medium. 
After 6 weeks, total cells were counted and 1500 cells 
were plated into methylcellulose for CFU assay as 
described above and colonies were counted after 14 days 
using standard criteria.
Chemical inhibition of RING1A and 
erythropoietin-induced differentiation
Toxicity tests were performed to determine the 
tolerated concentration of the RING1 inhibitor PRT4165 
(Sigma-Aldrich). To assess an influence on erythroid 
differentiation, CD34+ bone marrow cells cultured as 
described above were treated with the well-tolerated 
concentrations of 12.5μM PRT4165 or DMSO for two 
weeks and with 2 U/ml erythropoietin during the second 
week. Then, cells were counted and split. 1500 cells were 
plated into methylcellulose and the remaining viable cells 
were analyzed by flow cytometry.
May-Grünwald-Giemsa staining
Cells were immobilized on glass slides by cytospin 
centrifugation (Thermo Scientific) at 300 rpm for 10 minutes. 
Once dried, cells were submerged in fixation May-Grünwald 
solution (Merck) for 5 minutes followed by 15 minutes in 
staining Giemsa solution (Merck). Cells were mounted with 
DPX Mountant for histology (Sigma-Aldrich).
High content data analysis
All data analysis was performed using publicly 
available datasets. The MDS datasets GSE4619 [23] or 
GSE19429 [24] were generated using cDNA from CD34+ 
cells from 55 or 183 MDS patients followed by microarray 
analysis using the Affymetrix GeneChip Human Genome 
U133 Plus 2.0 arrays. The arrays were normalized using 
Robust Multi-Array Average expression measure (RMA) 
and differential expression analysis performed using a 
linear model and the Limma package [51]. Moderated 
t-statistics were generated and significance was assessed 
using log fold change and P-value.
To analyze the differentiation from HSC to fully 
mature polymorphonuclear granulocytes the GEO 
series GSE42519 was used, which consists of data from 
isolated bone marrow cell populations that represent 
eight sequential stages in the differentiation from HSC 
to fully mature polymorphonuclear granulocytes [25]. 
The normalized expression values were extracted and 
unsupervised hierarchical clustering performed using the 
heatmap.2 function from gplots (https://cran.r-project.org/
package=gplots).
In order to compare RNA expression and MDS 
clinical features, the dataset GSE15061 was utilized [32]. 
This dataset consists of expression data from mononuclear 
bone marrow cells from 139 MDS patients generated 
using the Affymetrix GeneChip Human Genome U133 
Plus 2.0 array. The normalized expression values were 
extracted and correlation analysis performed using the 
R core package (http://www.R-project.org). Parameters 
considered for the correlation analysis were number 
of cytopenias at diagnosis, percentage of blasts in bone 
marrow and scoring according to IPSS.
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Statistics
If not indicated otherwise, p-values are calculated 
using paired, two-tailed T-tests.
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